Therapy focus – First-line lung cancer is an Opdivo vs Keytruda showdown

Date June 10, 2016

New data from early studies of checkpoint inhibitors in non-small cell lung cancer emerged at Asco, but none represented the results that the oncology field is awaiting most eagerly.

This accolade is reserved for the outcome of the phase III studies of Merck & Co’s Keytruda and Bristol-Myers Squibb’s Opdivo in first-line NSCLC therapy that will likely determine how the most commercially important cancer indication divides up among competing agents. Other immunotherapies are waiting in the wings, but the initial battle hinges on the breadth of the possible NSCLC label that Opdivo and Keytruda might boast (see table below).

The Bristol and Merck drugs are both approved as second-line therapies in NSCLC, but Keytruda is indicated only for those patients whose tumour cells express PD-L1. Opdivo has no such restriction, and – with no need to conduct a companion test – has so far captured the lion’s share of NSCLC patients. In other respects the two agents are considered interchangeable, despite minor differences in efficacy and dosing schedules.

Up the chain

With these agents already established as the second-line standard, the next change in the field is expected to be a move to first-line therapy. This will be determined by the outcome of the Keynote-024 study of Keytruda, which is due imminently, and the Checkmate-026 trial of Opdivo, expected in November.

The two studies are very similar and test the drugs against platinum-based chemotherapy in the subgroup of patients who are “strong” expressers of PD-L1 – about 25% of patients. With Merck having already lost its first-mover checkpoint inhibitor advantage, the group's lead in first-line NSCLC could be a chance to even the balance against Bristol.

However, any advantage might be short-lived. This is because Bristol's study has a statistical design allowing all-comers to be tested if an initial benefit in "high PD-L1 expressors" is shown. Merck's Keynote-025 is recruiting only PD-L1-high patients.

Clearly an additional advantage can come from better efficacy. Later studies test the drugs in combination with first-line chemotherapy and/or in broader groups based on PD-L1 expression.


But what of the data in first-line therapy emerging at Asco? One closely watched presentation concerned Keynote-021, a multi-cohort phase I/II study of Keytruda plus platinum-doublet chemotherapy, immunotherapy or EGFR-targeted therapy.

In one cohort 24 patients who received Alimta, carboplatin and Keytruda as a front-line treatment followed by Alimta/Keytruda for up to two years achieved an objective response rate (ORR) of 71%. Furthermore, those with the highest level of PD-L1 expression showed a 75% ORR.

Pooled data from Checkmate-012, a phase Ib study of Opdivo and Yervoy, were also presented. Here the combination achieved an ORR of 39% to 47%, depending on dose. ORR averaged 57% in PD-L1-positive patients and reached 92% in the highest (≥50%) PD-L1 expressers. In patients who tested PD-L1-negative the ORR for the combination regimen was just 15%.

This combination is being assessed in the phase III Checkmate-227 trial, which has a projected completion date of January 2018. But competition in the NSCLC market looms, and a review by EP Vantage shows 23 phase III studies under way with PD-1/PD-L1 inhibitors. 

Selected late-stage immuno-oncology trials in non-small cell lung cancer 
Project/company  Enrolment  Study name  Trial ID  Data  
(Bristol-Myers Squibb) 
535  Checkmate-026  NCT02041533  Nov 2016 
  1,980  Checkmate-227  NCT02477826  Jan 2018 
  500  Checkmate-078  NCT02613507  May 2018 
Keytruda (Merck & Co)  305  Keynote-024  NCT02142738  Jun 2016 
  570  Keynote-189  NCT02578680  Sep 2017 
  1,240  Keynote-042  NCT02220894  Feb 2018 
  560  Keynote-407  NCT02775435  Mar 2018 
Tecentriq (Roche)  1,200  IMpower150  NCT02366143  Jan 2017 
  1,225  Oak  NCT02008227  Jun 2017 
  400  IMpower110  NCT02409342  Apr 2018 
Durvalumab (AstraZeneca)  730  Arctic  NCT02352948  Feb 2017 
  702  Pacific   NCT02125461  May 2017 
  350  Caural  NCT02454933  Aug 2018 
  800  Nepture   NCT02542293  Oct 2018 
Avelumab (Merck KGaA/Pfizer)  420  Javelin Lung 100  NCT02576574  Aug 2017 
  650  Javelin Lung 200  NCT02395172  Oct 2017 

The first threat is likely to come from Roche’s Tecentriq, which is under review for second-line use in PD-L1 expressers, with a PDUFA date of October 19. A more direct threat could come in the form of Pfizer/Merck KGaA’s avelumab, which is being studied in the first-line indication in the Javelin lung 100 study.

AstraZeneca has a number of phase III studies under way with durvalumab, though earlier this year it made a decision that, irrespective of their outcome, it would not file this project as monotherapy, instead seeking to build an immuno-oncology franchise based on the combination with tremelimumab. Its first study of this combination in PD-L1-negative third line-patients reads out in early 2017.

Either way, any lead that Keytruda will have thanks to its earlier data readout is likely to be short lived.

To contact the writer of this story email Robin Davison at news@epvantage.com or follow @RobinDavison2 on Twitter

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd